Published in J Clin Oncol on July 22, 2013
Adrenocortical carcinoma. Endocr Rev (2013) 1.46
Comprehensive Pan-Genomic Characterization of Adrenocortical Carcinoma. Cancer Cell (2016) 1.06
Genetics and epigenetics of adrenocortical tumors. Mol Cell Endocrinol (2013) 1.01
Adrenocortical carcinoma: the management of metastatic disease. Crit Rev Oncol Hematol (2014) 0.89
The evolution of colorectal cancer genetics-Part 2: clinical implications and applications. J Gastrointest Oncol (2014) 0.86
Adrenocortical Carcinoma: Impact of Surgical Margin Status on Long-Term Outcomes. Ann Surg Oncol (2015) 0.84
Pediatric adrenocortical tumors: what they can tell us on adrenal development and comparison with adult adrenal tumors. Front Endocrinol (Lausanne) (2015) 0.81
The challenge of developmental therapeutics for adrenocortical carcinoma. Oncotarget (2016) 0.81
Next-generation sequencing of adrenocortical carcinoma reveals new routes to targeted therapies. J Clin Pathol (2014) 0.80
Diagnostic and prognostic features in adrenocortical carcinoma: a single institution case series and review of the literature. World J Surg Oncol (2015) 0.78
PMS2 gene mutation results in DNA mismatch repair system failure in a case of adult granulosa cell tumor. J Ovarian Res (2017) 0.75
Familial Adrenocortical Carcinoma in Association With Lynch Syndrome. J Clin Endocrinol Metab (2016) 0.75
Adrenocortical carcinoma mimicking lung cancer and responding to vinorelbine/carboplatin and pemetrexed/carboplatin. BMJ Case Rep (2014) 0.75
Adrenocortical carcinoma: modern management and evolving treatment strategies. Int J Endocr Oncol (2016) 0.75
Revised Bethesda Guidelines for hereditary nonpolyposis colorectal cancer (Lynch syndrome) and microsatellite instability. J Natl Cancer Inst (2004) 14.97
Clues to the pathogenesis of familial colorectal cancer. Science (1993) 14.52
Microsatellite instability in cancer of the proximal colon. Science (1993) 14.51
Ubiquitous somatic mutations in simple repeated sequences reveal a new mechanism for colonic carcinogenesis. Nature (1993) 12.74
Screening for the Lynch syndrome (hereditary nonpolyposis colorectal cancer). N Engl J Med (2005) 9.39
Controlled 15-year trial on screening for colorectal cancer in families with hereditary nonpolyposis colorectal cancer. Gastroenterology (2000) 8.41
Cancer risk in mutation carriers of DNA-mismatch-repair genes. Int J Cancer (1999) 6.73
Prediction of germline mutations and cancer risk in the Lynch syndrome. JAMA (2006) 4.34
Screening for Lynch syndrome (hereditary nonpolyposis colorectal cancer) among endometrial cancer patients. Cancer Res (2006) 4.26
An inherited p53 mutation that contributes in a tissue-specific manner to pediatric adrenal cortical carcinoma. Proc Natl Acad Sci U S A (2001) 3.14
Cancer risk in hereditary nonpolyposis colorectal cancer due to MSH6 mutations: impact on counseling and surveillance. Gastroenterology (2004) 2.90
Hereditary factors in cancer. Study of two large midwestern kindreds. Arch Intern Med (1966) 2.86
Health benefits and cost-effectiveness of primary genetic screening for Lynch syndrome in the general population. Cancer Prev Res (Phila) (2010) 2.86
Life-time risk of different cancers in hereditary non-polyposis colorectal cancer (HNPCC) syndrome. Int J Cancer (1995) 2.85
Identification of Lynch syndrome among patients with colorectal cancer. JAMA (2012) 2.77
Calculation of risk of colorectal and endometrial cancer among patients with Lynch syndrome. Gastroenterology (2009) 2.75
Germline TP53 mutations and Li-Fraumeni syndrome. Hum Mutat (2003) 2.45
Reflex immunohistochemistry and microsatellite instability testing of colorectal tumors for Lynch syndrome among US cancer programs and follow-up of abnormal results. J Clin Oncol (2012) 2.40
Colorectal and other cancer risks for carriers and noncarriers from families with a DNA mismatch repair gene mutation: a prospective cohort study. J Clin Oncol (2012) 2.22
Extent of disease at presentation and outcome for adrenocortical carcinoma: have we made progress? World J Surg (2006) 1.78
Sensitivity and predictive value of criteria for p53 germline mutation screening. J Med Genet (2001) 1.77
Endometrial cancer and Lynch syndrome: clinical and pathologic considerations. Cancer Control (2009) 1.66
Are there low-penetrance TP53 Alleles? evidence from childhood adrenocortical tumors. Am J Hum Genet (1999) 1.57
Mismatch repair gene PMS2: disease-causing germline mutations are frequent in patients whose tumors stain negative for PMS2 protein, but paralogous genes obscure mutation detection and interpretation. Cancer Res (2004) 1.55
Adrenocortical neoplasms with hemihypertrophy, brain tumors, and other disorders. J Pediatr (1967) 1.55
Development of a fluorescent multiplex assay for detection of MSI-High tumors. Dis Markers (2004) 1.50
Unusual DNA mismatch repair-deficient tumors in Lynch syndrome: a report of new cases and review of the literature. Hum Pathol (2012) 1.20
Adrenal involvement in multiple endocrine neoplasia type 1. World J Surg (2002) 1.13
TP53 germline mutations in adult patients with adrenocortical carcinoma. J Clin Endocrinol Metab (2011) 1.04
Association of adrenocortical carcinoma with familial cancer susceptibility syndromes. Mol Cell Endocrinol (2011) 1.01
Prevalence of germline TP53 mutations in a prospective series of unselected patients with adrenocortical carcinoma. J Clin Endocrinol Metab (2012) 1.00
Unusual tumors associated with the hereditary nonpolyposis colorectal cancer syndrome. Mod Pathol (2004) 0.95
Screening of patients with multiple endocrine neoplasia type 1 (MEN-1): a critical analysis of its value. World J Surg (2009) 0.92
Adrenocortical adenocarcinoma in an MSH2 carrier: coincidence or causal relation? Hum Pathol (2000) 0.90
Mismatch repair protein deficiency is common in sebaceous neoplasms and suggests the importance of screening for Lynch syndrome. Am J Dermatopathol (2013) 0.88
Adrenocortical carcinoma, an unusual extracolonic tumor associated with Lynch II syndrome. Fam Cancer (2011) 0.83
MSH6 mutations are frequent in hereditary nonpolyposis colorectal cancer families with normal pMSH6 expression as detected by immunohistochemistry. Appl Immunohistochem Mol Morphol (2012) 0.81
Gene-expression profiles predict survival of patients with lung adenocarcinoma. Nat Med (2002) 21.28
A simple noninvasive index can predict both significant fibrosis and cirrhosis in patients with chronic hepatitis C. Hepatology (2003) 16.40
Gene expression-based survival prediction in lung adenocarcinoma: a multi-site, blinded validation study. Nat Med (2008) 10.12
SOX2 is an amplified lineage-survival oncogene in lung and esophageal squamous cell carcinomas. Nat Genet (2009) 7.48
p53-mediated activation of miRNA34 candidate tumor-suppressor genes. Curr Biol (2007) 6.87
Statins and the risk of colorectal cancer. N Engl J Med (2005) 6.86
Genome-wide association scan identifies a colorectal cancer susceptibility locus on 11q23 and replicates risk loci at 8q24 and 18q21. Nat Genet (2008) 6.75
Personalized oncology through integrative high-throughput sequencing: a pilot study. Sci Transl Med (2011) 5.82
Incidence of initial local therapy among men with lower-risk prostate cancer in the United States. J Natl Cancer Inst (2006) 5.42
EML4-ALK fusion lung cancer: a rare acquired event. Neoplasia (2008) 5.22
Rearrangements of the RAF kinase pathway in prostate cancer, gastric cancer and melanoma. Nat Med (2010) 4.81
Network modeling links breast cancer susceptibility and centrosome dysfunction. Nat Genet (2007) 4.69
Discordant protein and mRNA expression in lung adenocarcinomas. Mol Cell Proteomics (2002) 4.56
Prediction of germline mutations and cancer risk in the Lynch syndrome. JAMA (2006) 4.34
Molecular profiling of pancreatic adenocarcinoma and chronic pancreatitis identifies multiple genes differentially regulated in pancreatic cancer. Cancer Res (2003) 4.30
Statins and cancer prevention. Nat Rev Cancer (2005) 4.12
Frequency and spectrum of cancers in the Peutz-Jeghers syndrome. Clin Cancer Res (2006) 3.81
Interlaboratory comparability study of cancer gene expression analysis using oligonucleotide microarrays. Clin Cancer Res (2005) 3.79
Gene expression in ovarian cancer reflects both morphology and biological behavior, distinguishing clear cell from other poor-prognosis ovarian carcinomas. Cancer Res (2002) 3.62
Small changes in expression affect predisposition to tumorigenesis. Nat Genet (2001) 3.37
American Society of Clinical Oncology Expert Statement: collection and use of a cancer family history for oncology providers. J Clin Oncol (2014) 3.07
Mouse model of colonic adenoma-carcinoma progression based on somatic Apc inactivation. Cancer Res (2007) 2.97
Health benefits and cost-effectiveness of primary genetic screening for Lynch syndrome in the general population. Cancer Prev Res (Phila) (2010) 2.86
The histone deacetylase SIRT6 is a tumor suppressor that controls cancer metabolism. Cell (2012) 2.78
Functionally recurrent rearrangements of the MAST kinase and Notch gene families in breast cancer. Nat Med (2011) 2.77
Calculation of risk of colorectal and endometrial cancer among patients with Lynch syndrome. Gastroenterology (2009) 2.75
Prediction of MLH1 and MSH2 mutations in Lynch syndrome. JAMA (2006) 2.73
Hepatic fat fraction: MR imaging for quantitative measurement and display--early experience. Radiology (2005) 2.69
Anti-oncogenic role of the endoplasmic reticulum differentially activated by mutations in the MAPK pathway. Nat Cell Biol (2006) 2.58
Identification of Genetic Susceptibility Loci for Colorectal Tumors in a Genome-Wide Meta-analysis. Gastroenterology (2012) 2.57
Crosstalk between tumor and endothelial cells promotes tumor angiogenesis by MAPK activation of Notch signaling. Cancer Cell (2005) 2.47
Genetic/familial high-risk assessment: breast and ovarian. J Natl Compr Canc Netw (2010) 2.45
Microsatellite instability in colorectal cancer-the stable evidence. Nat Rev Clin Oncol (2010) 2.43
Pretreatment health behaviors predict survival among patients with head and neck squamous cell carcinoma. J Clin Oncol (2009) 2.38
Meta-analysis of new genome-wide association studies of colorectal cancer risk. Hum Genet (2011) 2.35
Risk of pancreatic cancer in families with Lynch syndrome. JAMA (2009) 2.32
Genetic variation in 8q24 associated with risk of colorectal cancer. Cancer Biol Ther (2007) 2.32
The yield of colonoscopy in patients with non-constipated irritable bowel syndrome: results from a prospective, controlled US trial. Am J Gastroenterol (2010) 2.30
Regenerating islet-derived 3-alpha is a biomarker of gastrointestinal graft-versus-host disease. Blood (2011) 2.24
Malignant pheochromocytoma: current status and initiatives for future progress. Endocr Relat Cancer (2004) 2.20
Correlation between genetic alterations and microscopic features, clinical manifestations, and prognostic characteristics of thyroid papillary carcinomas. Am J Surg Pathol (2006) 2.15
Frequency of KRAS, BRAF, and NRAS mutations in colorectal cancer. Genes Chromosomes Cancer (2011) 2.14
NCCN clinical practice guidelines in oncology. Colorectal cancer screening. J Natl Compr Canc Netw (2010) 2.13
The role of radiologic studies in the evaluation and management of primary hyperaldosteronism. Surgery (2008) 2.11
Lifetime risk of melanoma in CDKN2A mutation carriers in a population-based sample. J Natl Cancer Inst (2005) 2.10
Telomere protection by mammalian Pot1 requires interaction with Tpp1. Nat Struct Mol Biol (2007) 2.09
One-year intense nutritional counseling results in histological improvement in patients with non-alcoholic steatohepatitis: a pilot study. Am J Gastroenterol (2005) 2.04
Tests for gene-environment interaction from case-control data: a novel study of type I error, power and designs. Genet Epidemiol (2008) 2.04
BLM heterozygosity and the risk of colorectal cancer. Science (2002) 2.03
B-Raf(V600E) and thrombospondin-1 promote thyroid cancer progression. Proc Natl Acad Sci U S A (2010) 2.03
Risk of colorectal and endometrial cancers in EPCAM deletion-positive Lynch syndrome: a cohort study. Lancet Oncol (2010) 1.98
Phenotype of microsatellite unstable colorectal carcinomas: Well-differentiated and focally mucinous tumors and the absence of dirty necrosis correlate with microsatellite instability. Am J Surg Pathol (2003) 1.97
Comparison of seven methods for producing Affymetrix expression scores based on False Discovery Rates in disease profiling data. BMC Bioinformatics (2005) 1.96
Septin 9 methylated DNA is a sensitive and specific blood test for colorectal cancer. BMC Med (2011) 1.93
Metabolic syndrome is associated with greater histologic severity, higher carbohydrate, and lower fat diet in patients with NAFLD. Am J Gastroenterol (2006) 1.91
Protein profiles associated with survival in lung adenocarcinoma. Proc Natl Acad Sci U S A (2003) 1.86
BRAF and NRAS mutations in melanoma and melanocytic nevi. Melanoma Res (2006) 1.85
Use of bisphosphonates and reduced risk of colorectal cancer. J Clin Oncol (2011) 1.84
Low Paneth cell numbers at onset of gastrointestinal graft-versus-host disease identify patients at high risk for nonrelapse mortality. Blood (2013) 1.82
Population-based study of natural variation in the melanocortin-1 receptor gene and melanoma. Cancer Res (2006) 1.80
A design for cancer case-control studies using only incident cases: experience with the GEM study of melanoma. Int J Epidemiol (2006) 1.80
BRCA1 and BRCA2 founder mutations and the risk of colorectal cancer. J Natl Cancer Inst (2004) 1.76
Accurate classification of MLH1/MSH2 missense variants with multivariate analysis of protein polymorphisms-mismatch repair (MAPP-MMR). Hum Mutat (2008) 1.76
Physician assessment of family cancer history and referral for genetic evaluation in colorectal cancer patients. Clin Gastroenterol Hepatol (2004) 1.76
Molecular classification and prognostication of adrenocortical tumors by transcriptome profiling. Clin Cancer Res (2009) 1.76
Jumbo forceps are superior to standard large-capacity forceps in obtaining diagnostically adequate inflammatory bowel disease surveillance biopsy specimens. Gastrointest Endosc (2007) 1.72
Characteristics and survival of interval and sporadic colorectal cancer patients: a nationwide population-based cohort study. Am J Gastroenterol (2013) 1.71
Hepatic steatosis in hepatitis C: comparison of diabetic and nondiabetic patients in the hepatitis C antiviral long-term treatment against cirrhosis trial. Clin Gastroenterol Hepatol (2007) 1.71
Resection of adrenocortical carcinoma is less complete and local recurrence occurs sooner and more often after laparoscopic adrenalectomy than after open adrenalectomy. Surgery (2012) 1.70
Testing gene-environment interaction in large-scale case-control association studies: possible choices and comparisons. Am J Epidemiol (2011) 1.69
MRE11 deficiency increases sensitivity to poly(ADP-ribose) polymerase inhibition in microsatellite unstable colorectal cancers. Cancer Res (2011) 1.68
Oncogenic KRAS is not necessary for Wnt signalling activation in APC-associated FAP adenomas. J Pathol (2010) 1.68
Proteomic analysis of lung adenocarcinoma: identification of a highly expressed set of proteins in tumors. Clin Cancer Res (2002) 1.67
Genetic p53 deficiency partially rescues the adrenocortical dysplasia phenotype at the expense of increased tumorigenesis. Cancer Cell (2009) 1.67
RANTES expression is a predictor of survival in stage I lung adenocarcinoma. Clin Cancer Res (2002) 1.67
Microsatellite instability and DNA mismatch repair protein deficiency in Lynch syndrome colorectal polyps. Cancer Prev Res (Phila) (2012) 1.65
Relative frequency and morphology of cancers in STK11 mutation carriers. Gastroenterology (2004) 1.62
Development and validation of a colon cancer risk assessment tool for patients undergoing colonoscopy. Am J Gastroenterol (2009) 1.62
Sustained virologic response to therapy of recurrent hepatitis C after liver transplantation is related to early virologic response and dose adherence. Liver Transpl (2007) 1.61
Colon cancer, version 3.2014. J Natl Compr Canc Netw (2014) 1.59
A histologically defined subset of high-grade dysplasia in Barrett mucosa is predictive of associated carcinoma. Am J Clin Pathol (2009) 1.59
Genetic changes of Wnt pathway genes are common events in metaplastic carcinomas of the breast. Clin Cancer Res (2008) 1.58
In search of adrenocortical stem and progenitor cells. Endocr Rev (2009) 1.51
The prevalence of CDKN2A germ-line mutations and relative risk for cutaneous malignant melanoma: an international population-based study. Cancer Epidemiol Biomarkers Prev (2006) 1.51
Safety, tolerability, and pharmacokinetics of the anti-IGF-1R monoclonal antibody figitumumab in patients with refractory adrenocortical carcinoma. Cancer Chemother Pharmacol (2009) 1.50
An integrative approach to reveal driver gene fusions from paired-end sequencing data in cancer. Nat Biotechnol (2009) 1.47
Epigenetic silencing of engineered L1 retrotransposition events in human embryonic carcinoma cells. Nature (2010) 1.47
Targeted disruption of beta-catenin in Sf1-expressing cells impairs development and maintenance of the adrenal cortex. Development (2008) 1.46
Adrenocortical carcinoma. Endocr Rev (2013) 1.46
Genetic variation in 3-hydroxy-3-methylglutaryl CoA reductase modifies the chemopreventive activity of statins for colorectal cancer. Cancer Prev Res (Phila) (2010) 1.45